Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aclarion Inc (ACON)

Aclarion Inc (ACON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,303
  • Shares Outstanding, K 10,431
  • Annual Sales, $ 80 K
  • Annual Income, $ -4,910 K
  • EBIT $ -5 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.44
  • Price/Sales 15.94
  • Price/Cash Flow N/A
  • Price/Book 0.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.74
  • Most Recent Earnings $-0.15 on 11/14/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.15
  • Number of Estimates 1
  • High Estimate -0.15
  • Low Estimate -0.15
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1000 +24.90%
on 12/20/24
0.2040 -38.77%
on 12/10/24
-0.0515 (-29.20%)
since 11/20/24
3-Month
0.1000 +24.90%
on 12/20/24
0.2385 -47.63%
on 10/22/24
-0.0521 (-29.44%)
since 09/20/24
52-Week
0.1000 +24.90%
on 12/20/24
6.7500 -98.15%
on 01/08/24
-5.4591 (-97.76%)
since 12/20/23

Most Recent Stories

More News
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit...

IMRN : 1.9600 (-1.75%)
ULY : 0.5030 (-4.14%)
IMUX : 1.0000 (-3.85%)
NMTC : 0.7582 (+0.03%)
SNGX : 2.95 (-4.22%)
TMG.VN : 0.190 (unch)
BLGO : 0.1950 (+8.64%)
FET : 14.21 (-1.80%)
ACFN : 18.0000 (-0.55%)
NRBO : 2.36 (+0.43%)
TGCB : 0.0800 (-15.79%)
SOTK : 4.23 (-4.73%)
Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

ACONW : 0.0250 (-1.19%)
ACON : 0.1249 (+8.99%)
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

ACONW : 0.0250 (-1.19%)
ACON : 0.1249 (+8.99%)
Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event

Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"),  a healthcare technology company that is leveraging biomarkers...

ACON : 0.1249 (+8.99%)
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan

Initial findings from the EVAL study are expected to be released in Q4 2022

ACON : 0.1249 (+8.99%)
ACONW : 0.0250 (-1.19%)
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain

Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years

ACON : 0.1249 (+8.99%)
ACONW : 0.0250 (-1.19%)
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering

SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"),...

ACON : 0.1249 (+8.99%)
ACONW : 0.0250 (-1.19%)
Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering

SAN MATEO, CA / ACCESSWIRE / April 21, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"),...

ACON : 0.1249 (+8.99%)
ACONW : 0.0250 (-1.19%)

Business Summary

Aclarion Inc. is a healthcare technology company which leverages Magnetic Resonance Spectroscopy and a proprietary biomarker to optimize clinical treatments. The Company is also researching the application of AI and machine learning platforms to analyze both the raw spectroscopy data and the post-processed...

See More

Key Turning Points

3rd Resistance Point 0.1749
2nd Resistance Point 0.1550
1st Resistance Point 0.1399
Last Price 0.1249
1st Support Level 0.1049
2nd Support Level 0.0850
3rd Support Level 0.0699

See More

52-Week High 6.7500
Fibonacci 61.8% 4.2097
Fibonacci 50% 3.4250
Fibonacci 38.2% 2.6403
Last Price 0.1249
52-Week Low 0.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar